Abstract
Natural product extracts are a rich source of small molecules that display antitumor activity. Cantharidin, in the form of the dried body of the Chinese blister beetles: Mylabris phalerata or M. cichorii, displays antitumor activity and induces apoptosis in many types of tumor cells. Cantharidin has been used as an anticancer agent by the Chinese for the treatment of hepatoma and oesophageal carcinoma for a long time. Although cantharidin is a natural toxin that possesses potent anti-tumor properties, its clinical application is limited due to severe side-effects and highly toxic nature. Therefore, some modified cantharidin analogues are synthesized chemically in order to achieve a comparable antitumour property to the mother compound but simultaneously produce a less toxic effect on non-cancer cells. In recent years, based on the structure of cantharidin, there has been intense interest in developing potent and selective inhibitors of PP1 and PP2A on tumour cells. Though numerous analogues of cantharidin have been synthesized and researched with tumour cell lines, there is little success on clinical application because of the potential toxicity of cantharidin derivates. The focus of this review is to describe how cantharidin and cantharidin derivates participate in antitumour processes in tumour cells, and discuss the molecular mechanisms of cantharidin and cantharidin derivates on tumour cells.
Keywords: Cantharidin, cantharidin derivates, tumour cell, molecular mechanism
Anti-Cancer Agents in Medicinal Chemistry
Title: The Effects of Cantharidin and Cantharidin Derivates on Tumour Cells
Volume: 9 Issue: 4
Author(s): Dongwu Liu and Zhiwei Chen
Affiliation:
Keywords: Cantharidin, cantharidin derivates, tumour cell, molecular mechanism
Abstract: Natural product extracts are a rich source of small molecules that display antitumor activity. Cantharidin, in the form of the dried body of the Chinese blister beetles: Mylabris phalerata or M. cichorii, displays antitumor activity and induces apoptosis in many types of tumor cells. Cantharidin has been used as an anticancer agent by the Chinese for the treatment of hepatoma and oesophageal carcinoma for a long time. Although cantharidin is a natural toxin that possesses potent anti-tumor properties, its clinical application is limited due to severe side-effects and highly toxic nature. Therefore, some modified cantharidin analogues are synthesized chemically in order to achieve a comparable antitumour property to the mother compound but simultaneously produce a less toxic effect on non-cancer cells. In recent years, based on the structure of cantharidin, there has been intense interest in developing potent and selective inhibitors of PP1 and PP2A on tumour cells. Though numerous analogues of cantharidin have been synthesized and researched with tumour cell lines, there is little success on clinical application because of the potential toxicity of cantharidin derivates. The focus of this review is to describe how cantharidin and cantharidin derivates participate in antitumour processes in tumour cells, and discuss the molecular mechanisms of cantharidin and cantharidin derivates on tumour cells.
Export Options
About this article
Cite this article as:
Liu Dongwu and Chen Zhiwei, The Effects of Cantharidin and Cantharidin Derivates on Tumour Cells, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (4) . https://dx.doi.org/10.2174/1871520610909040392
DOI https://dx.doi.org/10.2174/1871520610909040392 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Advances in Nanomedicines and Targeted Therapies for Colorectal Cancer
Colorectal cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in treatment strategies. Conventional therapies often face limitations such as systemic toxicity, drug resistance, and suboptimal targeting. The advent of nanomedicines and innovative drug delivery systems offers new hope for overcoming these challenges and ...read more
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes that aid in stabilizing chromosomal makeup. The resynthesis of telomeres is supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no telomerase activity in human somatic cells, but the stem cells and germ cells undergo ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The MYC Oncogene as a Cancer Drug Target
Current Cancer Drug Targets MicroRNAs in Tumorigenesis
Current Pharmaceutical Biotechnology Photodynamic Therapy: The Development of New Photosensitisers
Anti-Cancer Agents in Medicinal Chemistry Intracellular Trafficking of Plasmids for Gene Therapy: Mechanisms of Cytoplasmic Movement and Nuclear Import
Current Gene Therapy Poly(ADP-ribose)polymerase Inhibition - Where Now?
Current Medicinal Chemistry A Deeply Quiescent Subset of CML LSC depend on FAO yet Avoid Deleterious ROS by Suppressing Mitochondrial Complex I
Current Molecular Pharmacology Prostate Cancer, miRNAs, Metallothioneins and Resistance to Cytostatic Drugs
Current Medicinal Chemistry The Involvement of Heat Shock Proteins and Related Molecules in the Resistance to Therapies in Breast and Gynecologic Cancer
Current Cancer Therapy Reviews Recent Patents on Glioblastoma Signaling
Recent Patents on Biomarkers Tyrosine Kinase Inhibitors
Current Cancer Drug Targets Status of Flavonols as P-Glycoprotein Inhibitors in Cancer Chemotherapy
Current Cancer Therapy Reviews Sphere Formation Assay is not an Effective Method for Cancer Stem Cell Derivation and Characterization from the Caco-2 Colorectal Cell Line
Current Stem Cell Research & Therapy Bench to Bedside Targeting of FLT3 in Acute Leukemia
Current Drug Targets Use of Cell Lines in the Investigation of Pharmacogenetic Loci
Current Pharmaceutical Design Emerging Roles of MicroRNA-22 in Human Disease and Normal Physiology
Current Molecular Medicine Epigenetic Modulators as Treatment Alternative to Diverse Types of Cancer
Current Medicinal Chemistry The Epithelial-Mesenchymal Transition and Cancer Stem Cells: Functional and Mechanistic Links
Current Pharmaceutical Design Doxsaliform: A Novel N-Mannich Base Prodrug of a Doxorubicin Formaldehyde Conjugate
Letters in Drug Design & Discovery Developmental Immunotoxicity (DIT) in Drug Safety Testing: Matching DIT Testing to Adverse Outcomes and Childhood Disease Risk
Current Drug Safety Therapeutic Targets in Triple Negative Breast Cancer - Where are we now?
Recent Patents on Anti-Cancer Drug Discovery